Clinical Genomics Takes Hold in Iowa: Colleen Campbell, IIHG


Colleen Campbell, Assistant Director, University of Iowa - Iowa Institute for Human Genetics

Bio and Contact Info

Listen (2:35) How are you implementing genomic medicine?

Listen (3:17) Pharmacogenetic pilot with CYP219

Listen (8:24) How are you educating physicians?

Listen (2:32) Which patients are getting their exomes sequenced?

Listen (5:55) What are you doing with secondary and incidental findings?

Listen (1:30) Technical challenges?

Listen (3:33) History of IIHG

Today we take you to the front lines of clinical genomics.

Colleen Campbell is the assistant director at the Iowa Institute of Human Genetics (IIHG), a statewide resource devoted to understanding the extent and meaning of human DNA sequence variation. In March of this year, the IIHG at the University of Iowa began offering whole exome sequencing as well as some pharmacogenomic testing.

In today's interview, Colleen shares with us some practical stories outlining just how the IIHG is bringing genomics into the clinic. How did she and her colleagues go about deciding which pharmacogenomic tests to offer, and how are they dealing with the issue of incidental findings? As both a geneticist and a genetic counselor, Colleen offers a comprehensive, behind the scenes view on a story that is unfolding around the world.

At Mendelspod, we hear a lot about the challenge of educating clinicians on genomics. This has been a key area of focus for Colleen and her colleagues. The genomics team is engaging not only doctors but also nurses and the general community in new ways that could be a model for other clinics.

"Groups who are trying to implement these these kinds of tests need to think about educating the entire healthcare team," she says. "It's really important to educate everyone, from the person who greets the patient at the front desk to the nurses, the physicians, the genetic counselors, and the pharmacists--really anyone who's going to interact with the patient."

We end with a brief discussion about how the IIGH came about, and what are the next moves for Colleen and her team.

Podcast Sponsor: Integrated DNA Technologies - Introducing the evolution of NGS capture panels

Personalized Medicine for Pain with Simon Tate, Convergence Pharma


Simon Tate, Chief Scientific Officer, Convergence Pharmaceuticals

Bio and Contact Info

Listen (6:09) Sodium channel blockers and the Nav1.7 protein

Listen (4:17) How will your product compare with other pain meds?

Listen (5:06) Targeted clinical trials

Listen (3:36) A huge unmet medical need

Listen (4:28) Learning from the Vioxx scandal

Listen (2:31) Thoughts on marijuana use for pain

Did you know that you may have a gene which makes you experience more or less pain? Pain, that uncomfortable sensory experience we get when we stub our toe or suffer a cut, is the most common reason why we visit the doctor in America. It’s role is to send an alarm signal that something is wrong. Yet many people experience pain differently and at different levels based on their genetic makeup.

According to today's guest, Simon Tate, CSO for Convergence Pharmaceuticals, the area of pain presents a huge opportunity for personalized medicine.

His company's new technology acts by blocking sodium channels, conductive proteins that are part of the nervous system. Those born with a certain mutation of the SCN9A gene have "more active" sodium channels, and the clinical trials the company is running targets this population. The more active the channel, the more active becomes the drug molecule. According to Tate, sodium channel blockers have the potential to create a new paradigm in the treatment of chronic pain.

"Pain can be forgotten," says Simon about pain research. "In the US there is 50 times more funding going into cancer than into pain. . . . There's a huge unmet need here."

How is Convergence going about their clinical trials? And what can they learn from the Vioxx scandal? Simon answers these questions and more in today's show.

Podcast brought to you by: Chempetitive Group - "We love science. We love marketing. We love the idea of combining the two to make great things happen for your marketing communications."

Taking Pharmacogenomics to the Rest of the World: Howard McLeod

This podcast was originally aired on Sept. 14th, 2011

Sponsored by: BioConference Live


Dr. Howard McLeod, Director, PGENI, Bio and Contact Info

PGENI - Pharmacogenomics for Every Nation Initiative Listen (8:13) PGENI - Pharmacogenomics for Every Nation Initiative

Piggybacking on HIV education around the world Listen (2:27) Piggybacking on HIV education

Eight active centers around the world Listen (7:56) Eight active centers around the world

Examples of pharmacogenomics Listen (5:25) Examples of pharmacogenomics

FDA coming aboard Listen (3:25) FDA coming aboard

PGI at UNC: an interdisciplinary approach Listen (2:03) PGI at UNC: an interdisciplinary approach

The promise of lowering healthcare costs Listen (3:44) The promise of lowering healthcare costs

Other ways to use the genome Listen (3:44) Other ways to use the genome

Our guest today is Dr. Howard McLeod, an internationally recognized expert in pharmacogenomics. He’s the director for the UNC Institute for Pharmacogenomics and Individualized Therapy. He’s a member of the FDA’s subcommittee on Clinical Pharmacology, and is the director of the new PGENI, or Pharmacogenomics for Every Nation Initiative. Howard feels he has reached the highest career positions possible and now works to move along the field of pharmacogenomics in the best way possible.

New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup